|
ABEO | Abeona Therapeutics Inc. |
|
|
ABEO | Abeona Therapeutics Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 2.63 |
| Leverage | 27.33% |
| Market Cap | $ 176.4m |
| PE | 2.66 |
| Dividend Yield | 0.00% |
| Profit | $ 66.4m |
| Margin | 589.41% |
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for rare, life-threatening genetic diseases. The company is headquartered in New York, New York.